Why “Additive” Needs a Reference
A combination can produce a larger response than either drug alone without exceeding an additive expectation. The word additive therefore does not identify one universal numerical prediction: it depends on the reference model used to define what the combination would do in the absence of an interaction. Bliss independence, Loewe dose equivalence, and highest-single-agent (HSA) additivity use different reference assumptions. A combination may exceed one reference and not another.
The comparisons below concern pharmacodynamic effects at specified drug exposures, doses, times, and endpoints. If one drug changes the other drug’s exposure, a response difference can reflect that pharmacokinetic change rather than a direct pharmacodynamic interaction. The earlier material on decomposing exposure-mediated and direct pharmacodynamic interactions motivates holding or accounting for exposure when making this distinction.
For clarity, let \(E_A(a)\) and \(E_B(b)\) denote the effects of drugs A and B at doses \(a\) and \(b\), respectively. Effects are expressed on a common fractional scale from 0 to 1, where 0 is no effect relative to control and 1 is the maximum possible effect on the chosen scale. For an endpoint that decreases with treatment, define effect in the direction of benefit or inhibition, so a larger \(E\) consistently means a greater effect. Combination effects \(E_{AB}(a,b)\) must use the same endpoint, normalization, and direction.
Bliss Independence
Bliss independence treats the two drugs’ effects as independent chances of producing the defined effect. In a probabilistic interpretation, \(1-E_A(a)\) is the fraction not affected by A and \(1-E_B(b)\) is the fraction not affected by B. If the events “not affected by A” and “not affected by B” are independent, the fraction not affected by either is their product. The predicted affected fraction is therefore one minus that product.
This is the Bliss reference response. It is not the arithmetic sum of the two effects: the product term prevents the prediction from exceeding 1 when effects are fractions of a bounded total. The key assumption is independent action on this effect scale. The model does not require that the drugs have identical potencies or dose-response curve shapes, but it does require that the fractional effects are meaningfully measured on a common scale and that the independence assumption is defensible.
Worked Example: Calculating the Bliss Reference
Suppose a hypothetical experiment estimates a fractional inhibition of \(E_A(a)=0.40\) for A and \(E_B(b)=0.50\) for B at the selected doses. The observed combination inhibition is \(0.78\). Calculate the Bliss prediction and compare the observed response with it.
The Bliss formula is \(E_{\mathrm{Bliss}}=E_A+E_B-E_AE_B\). Substituting the single-agent effects gives \(E_{\mathrm{Bliss}}=0.40+0.50-(0.40)(0.50)=0.90-0.20=0.70\).
The hypothetical combination effect, 0.78, is \(0.78-0.70=0.08\), or 8 percentage points, above the Bliss reference. Descriptively, it exceeds the Bliss-independence prediction at these doses. That comparison does not by itself establish statistical evidence for an interaction, nor does it show that the drugs act independently in reality; it reports the result relative to the stated benchmark.
A response above the Bliss prediction is often called Bliss synergy, and one below it Bliss antagonism, provided the direction and scale have been defined as above. These labels are reference-specific. For example, if effects are expressed on an unbounded scale or the endpoint is normalized inconsistently across arms, the probability interpretation and bounded fractional formula may not be appropriate.
Loewe Dose Equivalence
Loewe additivity uses a different idea: at a specified effect level, one drug can be replaced by an equivalent dose of the other. Let \(D_A(e)\) be the dose of A that produces effect \(e\) when A is given alone, and define \(D_B(e)\) similarly. For a combination with doses \(a\) and \(b\) producing that same effect, each dose is expressed as a fraction of the corresponding single-agent dose needed to reach \(e\).
The Loewe additive isobole at effect \(e\) is the set of dose pairs for which \(\mathrm{CI}_{\mathrm{Loewe}}(e)=1\). The combination is below the additive dose requirement when the index is less than 1 and above it when the index is greater than 1. Equivalently, at a fixed dose pair, one can compare its observed effect with the effect predicted by the Loewe additive isobole. The dose-equivalence interpretation is clearest when both single-agent curves can attain the effect level being compared and dose-response relations are sufficiently well characterized.
This benchmark is based on dose substitutability: doses of A and B are treated as contributions toward the same effect, rather than as independent chances of effect. It is commonly motivated when drugs have sufficiently similar or interchangeable pharmacological actions. If their maximal effects differ, their curves do not cover the same effect range, or “equivalent dose” has no coherent interpretation, the Loewe comparison may be undefined or scientifically unsuitable at some effect levels.
Worked Example: Applying Loewe Dose Equivalence
Consider hypothetical single-agent curves with fractional effects \(E_A(a)=a/(10+a)\) and \(E_B(b)=b/(20+b)\), where doses are in mg. A combination at \(a=4\) mg and \(b=8\) mg has a measured effect of 0.50. Calculate the Loewe index at that effect.
For A alone, solve \(0.50=D_A/(10+D_A)\). Multiplying both sides by \(10+D_A\) gives \(5+0.50D_A=D_A\), so \(D_A(0.50)=10\) mg. Likewise, \(0.50=D_B/(20+D_B)\) gives \(D_B(0.50)=20\) mg.
Thus, \(\mathrm{CI}_{\mathrm{Loewe}}(0.50)=4/10+8/20=0.40+0.40=0.80\). The hypothetical combination reaches 50% effect using 80% of the total dose fractions required by the Loewe additive isobole. Its index is below 1, so the observed effect is above the Loewe-additive expectation at these doses.
For a direct check, under these curves the Loewe additive prediction at fixed doses solves \(a/D_A(e)+b/D_B(e)=1\). Since \(D_A(e)=10e/(1-e)\) and \(D_B(e)=20e/(1-e)\), the equation at \(a=4,b=8\) becomes \(0.4(1-e)/e+0.4(1-e)/e=1\). Therefore \(0.8(1-e)=e\), giving \(e=0.8/1.8=0.4444\). The observed 0.50 exceeds this predicted 0.4444, consistent with the index calculation.
The example’s index calculation uses the observed effect to find the single-agent equivalent doses. In applications, uncertainty in the single-agent curves and in the combination effect can affect that index; a point estimate alone does not show how precisely it is known. The dose-response curves should also be checked for monotonicity, adequate coverage of the effect level, and reliable estimation near the combination response.
Highest-Single-Agent Additivity
The HSA reference asks a simpler question: does the combination improve on the better of the two single-agent responses at the corresponding doses? For an effect where larger values mean greater benefit or inhibition, its reference is the maximum of the two single-agent effects.
A combination response equal to the HSA reference provides no improvement beyond the best single agent under this criterion. A response above it is a combination benefit relative to HSA; a response below it is worse than the best single-agent response. HSA does not model how the two effects combine mechanistically, and it does not claim that the drugs’ actions are independent or dose-substitutable. It is a practical, relatively undemanding benchmark for added benefit.
Worked Example: Comparing a Combination With HSA
In a hypothetical assay, A produces 0.35 fractional inhibition, B produces 0.50, and the combination produces 0.54 at the selected doses. Calculate the HSA reference and the improvement over it.
The HSA reference is \(\max(0.35,0.50)=0.50\). The observed combination exceeds it by \(0.54-0.50=0.04\), or 4 percentage points. Thus, it improves on the best single agent by the HSA criterion at those doses. This result alone does not say whether the combination exceeds Bliss independence or Loewe additivity; those are different reference calculations and require their own assumptions and inputs.
How the Benchmarks Differ
| Reference | Core assumption or question | Typical comparison | Main limitation |
|---|---|---|---|
| Bliss independence | Are the drugs’ fractional effects independent? | Observed response versus \(E_A+E_B-E_AE_B\) | Independence on the chosen response scale may not match the pharmacology. |
| Loewe dose equivalence | Can the drugs’ doses substitute for one another at a shared effect level? | Observed dose pair versus an isobole with index 1 | Effect-level dose equivalence can be unsuitable or undefined for dissimilar curves or unattainable effects. |
| Highest single agent | Does the combination outperform the best component alone? | Observed response versus \(\max(E_A,E_B)\) | It is a modest efficacy benchmark, not a detailed model of additive action. |
These benchmarks can yield different labels for the same data. In the Bliss example, the independent-action reference is 0.70, while HSA is 0.50. A hypothetical observed effect of 0.65 would exceed HSA but fall below Bliss. There is no contradiction: the combination improves on the best single agent yet does not reach the Bliss prediction. Loewe may give a third answer because it uses dose equivalents and single-agent dose-response curves rather than only the two effects at the selected doses.
Assumptions, Diagnostics, and Common Pitfalls
Before applying any benchmark, verify that the comparison uses the same endpoint, effect direction, observation time, and relevant exposure conditions across control, single-agent, and combination arms. A response measured before one drug reaches its effect site, for example, cannot automatically be compared with a response measured at a later equilibrium time. Concentrations or doses should represent the intended intervention; a combination-induced change in exposure can otherwise be mistaken for a pharmacodynamic departure from additivity.
Useful diagnostic checks include plotting each single-agent dose-response curve alongside the combination observations; checking that the curves are monotone over the analyzed range; confirming that all effects are on the stated scale; and examining whether the single-agent data bracket the effects used for Loewe inversion. For Bliss, inspect whether the measured fractional effects support the independent-action interpretation and whether the normalization produces values between 0 and 1. For HSA, verify that both monotherapies and the combination were assessed under comparable conditions. Replicate variability and uncertainty matter: a numerical difference from a reference is not automatically a reliable or clinically important difference.
Common mistake: “The combination response is greater than either single-agent response, so the drugs are synergistic.” This reasoning uses the HSA comparison but silently treats it as if it were every definition of additivity. The correction is to name the reference explicitly and calculate it: exceeding HSA establishes improvement on the best single agent, whereas Bliss and Loewe ask different questions and can set higher or otherwise different predictions.
A second pitfall is adding fractional effects directly and calling the result Bliss additivity. For effects 0.40 and 0.50, the arithmetic sum is 0.90, but the Bliss reference is \(0.40+0.50-(0.40)(0.50)=0.70\). A third is applying Loewe equivalence at an effect that one monotherapy cannot attain: the required single-agent dose \(D_A(e)\) or \(D_B(e)\) then does not exist as a finite dose, so the usual index is not defined for that comparison.
No benchmark is a universal biological law. Bliss may be a poor reference when actions are not independent on the chosen scale; Loewe may be hard to justify for agents with distinct, non-substitutable actions; and HSA does not quantify a mechanistic additive expectation. The appropriate choice should follow the scientific question and pharmacology, and conclusions should state the reference and effect scale rather than use “synergy” without qualification.
Specify endpoint, direction, time, normalization, and doses or exposures being compared.
Use Bliss for independent fractional action, Loewe for dose equivalence at a shared effect, or HSA for improvement over the best single agent.
Confirm comparable conditions, suitable single-agent curves, and a response scale appropriate to the selected reference.
Give the calculated reference, observed difference or index, units or percentage points, and the benchmark name.
Check Your Understanding
Answer each question using the stated reference, and then compare with the concise solutions.
- If hypothetical fractional effects are \(E_A=0.20\) and \(E_B=0.30\), what is the Bliss prediction?
- At an effect of 0.60, the single-agent equivalent doses are 12 mg for A and 24 mg for B. A combination of 3 mg A and 6 mg B produces that effect. What is its Loewe index, and how does it compare with the additive isobole?
- If A gives effect 0.45, B gives 0.40, and the combination gives 0.44, what does HSA say?
- Why can a combination exceed HSA without exceeding Bliss independence?
- What problem arises if a Loewe analysis requires a single-agent dose for an effect that the drug cannot attain?
Solutions. (1) \(0.20+0.30-(0.20)(0.30)=0.44\). (2) \(3/12+6/24=0.25+0.25=0.50\), below 1; it reaches the specified effect with fewer dose fractions than the Loewe additive isobole. (3) HSA is \(\max(0.45,0.40)=0.45\); the combination’s 0.44 does not improve on the best single agent. (4) HSA compares with the larger monotherapy effect, whereas Bliss predicts \(E_A+E_B-E_AE_B\), which can be larger; the benchmarks embody different assumptions. (5) The required equivalent dose is undefined or not finite, so the usual Loewe index cannot be calculated at that effect.